Cargando…

Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α

Psoriasis is a chronic cutaneous inflammatory disease. The immunopathogenesis is a complex interplay between T cells, dendritic cells and the epidermis in which T cells and dendritic cells maintain skin inflammation. Anti-tumour necrosis factor (anti-TNF)-α agents have been approved for therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langkilde, Ane, Olsen, Lene C., Sætrom, Pål, Drabløs, Finn, Besenbacher, Søren, Raaby, Line, Johansen, Claus, Iversen, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179238/ https://www.ncbi.nlm.nih.gov/pubmed/28005985 http://dx.doi.org/10.1371/journal.pone.0167437

Ejemplares similares

A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis
por: Raaby, Line, et al.
Publicado: (2010)

A manually curated ChIP-seq benchmark demonstrates room for improvement in current peak-finder programs
por: Rye, Morten Beck, et al.
Publicado: (2011)

Clustered ChIP-Seq-defined transcription factor binding sites and histone modifications map distinct classes of regulatory elements
por: Rye, Morten, et al.
Publicado: (2011)

Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence
por: Lombardi, G, et al.
Publicado: (2016)

A ChIP-Seq Benchmark Shows That Sequence Conservation Mainly Improves Detection of Strong Transcription Factor Binding Sites
por: Håndstad, Tony, et al.
Publicado: (2011)

Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab
por: Cludts, Isabelle, et al.
Publicado: (2017)

Cell-type specificity of ChIP-predicted transcription factor binding sites
por: Håndstad, Tony, et al.
Publicado: (2012)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Anti-TNF-Alpha-Induced Psoriasis – An Unusual Paradox
por: Sharma, Neel, et al.
Publicado: (2009)

Climatotherapy at the Dead Sea for psoriasis is a highly effective anti‐inflammatory treatment in the short term: An immunohistochemical study
por: Emmanuel, Thomas, et al.
Publicado: (2022)

Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics
por: Ben Abdallah, Hakim, et al.
Publicado: (2021)

Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor
por: Bustos, Rosa Helena, et al.
Publicado: (2018)

Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models
por: Tolstrup, Martin, et al.
Publicado: (2013)

Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study
por: Emmanuel, Thomas, et al.
Publicado: (2020)

The eGenVar data management system—cataloguing and sharing sensitive data and metadata for the life sciences
por: Razick, Sabry, et al.
Publicado: (2014)

Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?
por: Jiraskova Zakostelska, Zuzana, et al.
Publicado: (2023)

Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial
por: Pope, Janet, et al.
Publicado: (2012)

Effects of Adalimumab, an Anti-tumour Necrosis Factor-Alpha (TNF-α) Antibody, on Obese Diabetic Rats
por: Shuwa, Halima Ali, et al.
Publicado: (2018)

Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn's Disease Treated with Anti-TNF (Adalimumab)
por: Klarin, Ivo
Publicado: (2023)

Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis
por: Pirowska, Magdalena M., et al.
Publicado: (2015)

Interstitial lung disease due to anti-TNF use in the treatment of psoriasis()()
por: Turíbio, Débora Dorneles Cunha de Queiroz, et al.
Publicado: (2021)

A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine
por: Hansen, Maren F., et al.
Publicado: (2015)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab
por: Wang, Lei, et al.
Publicado: (2021)

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders
por: Engel, Sinah, et al.
Publicado: (2020)

MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy
por: Jezernik, Gregor, et al.
Publicado: (2023)

Adalimumab for severe psoriasis in Chilean paediatric patients()()
por: Armijo Fernandez, Daniela, et al.
Publicado: (2020)

Reactivation of Tuberculosis in Three Cases of Psoriasis after Initiation of Anti-TNF Therapy
por: Shaikha, Samya Abu, et al.
Publicado: (2012)

Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis
por: de Vasconcellos, Jaqueline Barbeito, et al.
Publicado: (2016)

High-throughput RNA sequencing from paired lesional- and non-lesional skin reveals major alterations in the psoriasis circRNAome
por: Moldovan, Liviu-Ionut, et al.
Publicado: (2019)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Anti-TNFα therapy in the management of psoriasis: experience of a state referral center()
por: Silva, Laura Maria Andrade, et al.
Publicado: (2014)

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
por: Cannizzaro, Maria Vittoria, et al.
Publicado: (2017)

CNVs Associated with Different Clinical Phenotypes of Psoriasis and Anti-TNF-Induced Palmoplantar Pustulosis
por: Reolid, Alejandra, et al.
Publicado: (2022)

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
por: Ding, Xiaoliang, et al.
Publicado: (2020)

Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis
por: Gibellini, Lara, et al.
Publicado: (2016)

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis
por: Simonini, Gabriele, et al.
Publicado: (2013)

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007)

Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
por: Yayli, Savas, et al.
Publicado: (2013)

Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
por: Saffra, Norman, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jok886tgdgi2tietnbdd0kqaik